Innate Pharma Announces AGM Voting Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- AGM Voting Results: On May 21, 2026, Innate Pharma held its Annual General Meeting in Marseille, where 94 votes were cast representing 34,921,313 voting rights, achieving a quorum of 37,136%, indicating strong shareholder support for the company's governance.
- Resolution Documentation: The company will publish all resolutions and related documents on its website under the 2026 AGM section, ensuring transparency and enhancing shareholder trust in the decision-making process, which is crucial for maintaining investor relations.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer patients, with a portfolio of potential first and/or best-in-class assets aimed at addressing high unmet medical needs, showcasing its robust R&D capabilities.
- Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies and academic institutions, including Sanofi and AstraZeneca, aimed at advancing innovation in immuno-oncology, thereby enhancing its market competitiveness and technological strength.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.200
Low
5.00
Averages
6.50
High
8.00
Current: 2.200
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma Announces AGM Voting Results
- AGM Voting Results: On May 21, 2026, Innate Pharma held its Annual General Meeting in Marseille, where 94 votes were cast representing 34,921,313 voting rights, achieving a quorum of 37,136%, indicating strong shareholder support for the company's governance.
- Resolution Documentation: The company will publish all resolutions and related documents on its website under the 2026 AGM section, ensuring transparency and enhancing shareholder trust in the decision-making process, which is crucial for maintaining investor relations.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer patients, with a portfolio of potential first and/or best-in-class assets aimed at addressing high unmet medical needs, showcasing its robust R&D capabilities.
- Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies and academic institutions, including Sanofi and AstraZeneca, aimed at advancing innovation in immuno-oncology, thereby enhancing its market competitiveness and technological strength.
See More
Innate Pharma to Participate in 2026 Investor Meetings
- Investor Meeting Participation: Innate Pharma SA will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 2-4, 2026, in New York, aiming to enhance investor interaction and elevate the company's visibility.
- Innovative Therapy Development: The company focuses on developing immunotherapies for cancer patients, advancing several potential first and/or best-in-class assets, including IPH4502 and lacutamab, addressing high unmet medical needs in the market.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca to drive innovation in immuno-oncology, showcasing its influence and technical strength within the industry.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, Maryland, Innate Pharma's global business strategy aims to better serve international markets and expand its operational footprint.
See More
Innate Pharma to Hold Investor Meetings in New York
- Investor Meeting Schedule: Innate Pharma will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026, where members of its executive team will engage in one-on-one meetings with investors, aiming to enhance the company's visibility in the capital markets and attract potential investors.
- Innovative Drug Development: The company is developing various immunotherapies for cancer, including the Nectin-4 ADC (IPH4502) for solid tumors and the anti-KIR3DL2 antibody (lacutamab) for cutaneous T cell lymphomas, which are expected to address high unmet medical needs and enhance the company's competitive position in the market.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, aiming to accelerate innovation in the field of immuno-oncology through these partnerships, further solidifying its position in the industry.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, Maryland, Innate Pharma's international presence facilitates its business expansion in global markets and attracts increased investor attention.
See More
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
- Trial Launch: On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in cancer treatment, particularly for patients with prostate, ovarian, and pancreatic cancers.
- FDA Approval: The IND application for GTB-5550 received FDA clearance in February 2026, with the trial structured as a basket trial prioritizing enrollment of advanced cancer patients who have failed prior therapies, demonstrating the company's commitment to addressing unmet medical needs.
- Strong Financial Position: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, thereby enhancing investor confidence in the progress of the clinical trial.
- Significant Market Potential: Targeting the estimated $362 billion global solid tumor market, the B7-H3 antigen has attracted multiple pharmaceutical companies, indicating a rapidly rising clinical translation potential in this competitive landscape.
See More
Innate Pharma Reports Q1 2026 Financial Results
- Cash Position: As of March 31, 2026, Innate Pharma reported cash, cash equivalents, and financial assets totaling €25.4 million, indicating robust liquidity management that supports future R&D and operational needs.
- Financial Liabilities: At the same date, the company's financial liabilities stood at €20.3 million, reflecting a manageable debt level that suggests prudent use of financial leverage, thereby reducing financial risk.
- Significant Revenue Growth: The company achieved revenue of €2.6 million in Q1, representing a 116.7% year-over-year increase, which highlights Innate Pharma's success in market demand and product promotion, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With rapid revenue growth and a solid financial position, Innate Pharma's competitive edge in the biopharmaceutical sector is likely to strengthen, attracting more investor interest in its future growth potential.
See More
Innate Pharma Reports Clinical Progress and Financial Update
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in cutaneous T-cell lymphoma in H2 2026, currently negotiating non-dilutive financing options to support this trial, indicating the company's ongoing commitment in this therapeutic area.
- Drug Safety and Efficacy: IPH4502 (Nectin-4 ADC) has shown a favorable safety profile and preliminary anti-tumor activity in its Phase 1 trial, with the maximum tolerated dose reached and enrollment nearing completion, suggesting significant potential in treating advanced solid tumors.
- Collaborative Research Advancements: The PACIFIC-9 Phase 3 trial, in collaboration with AstraZeneca, is progressing towards a planned data readout in H2 2026, reflecting positive developments in the company's strategic partnerships in non-small cell lung cancer.
- Financial Position: As of March 31, 2026, Innate Pharma reported cash and cash equivalents of €25.4 million, with an anticipated cash runway extending into Q3 2026, demonstrating robust financial management amid ongoing clinical developments.
See More
Innate Pharma Announces AGM Voting Results
- AGM Voting Results: On May 21, 2026, Innate Pharma held its Annual General Meeting in Marseille, where 94 votes were cast representing 34,921,313 voting rights, achieving a quorum of 37,136%, indicating strong shareholder support for the company's governance.
- Resolution Documentation: The company will publish all resolutions and related documents on its website under the 2026 AGM section, ensuring transparency and enhancing shareholder trust in the decision-making process, which is crucial for maintaining investor relations.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer patients, with a portfolio of potential first and/or best-in-class assets aimed at addressing high unmet medical needs, showcasing its robust R&D capabilities.
- Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies and academic institutions, including Sanofi and AstraZeneca, aimed at advancing innovation in immuno-oncology, thereby enhancing its market competitiveness and technological strength.
See More
Innate Pharma to Participate in 2026 Investor Meetings
- Investor Meeting Participation: Innate Pharma SA will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 2-4, 2026, in New York, aiming to enhance investor interaction and elevate the company's visibility.
- Innovative Therapy Development: The company focuses on developing immunotherapies for cancer patients, advancing several potential first and/or best-in-class assets, including IPH4502 and lacutamab, addressing high unmet medical needs in the market.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca to drive innovation in immuno-oncology, showcasing its influence and technical strength within the industry.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, Maryland, Innate Pharma's global business strategy aims to better serve international markets and expand its operational footprint.
See More
Innate Pharma to Hold Investor Meetings in New York
- Investor Meeting Schedule: Innate Pharma will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026, where members of its executive team will engage in one-on-one meetings with investors, aiming to enhance the company's visibility in the capital markets and attract potential investors.
- Innovative Drug Development: The company is developing various immunotherapies for cancer, including the Nectin-4 ADC (IPH4502) for solid tumors and the anti-KIR3DL2 antibody (lacutamab) for cutaneous T cell lymphomas, which are expected to address high unmet medical needs and enhance the company's competitive position in the market.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, aiming to accelerate innovation in the field of immuno-oncology through these partnerships, further solidifying its position in the industry.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, Maryland, Innate Pharma's international presence facilitates its business expansion in global markets and attracts increased investor attention.
See More
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
- Trial Launch: On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in cancer treatment, particularly for patients with prostate, ovarian, and pancreatic cancers.
- FDA Approval: The IND application for GTB-5550 received FDA clearance in February 2026, with the trial structured as a basket trial prioritizing enrollment of advanced cancer patients who have failed prior therapies, demonstrating the company's commitment to addressing unmet medical needs.
- Strong Financial Position: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, thereby enhancing investor confidence in the progress of the clinical trial.
- Significant Market Potential: Targeting the estimated $362 billion global solid tumor market, the B7-H3 antigen has attracted multiple pharmaceutical companies, indicating a rapidly rising clinical translation potential in this competitive landscape.
See More
Innate Pharma Reports Q1 2026 Financial Results
- Cash Position: As of March 31, 2026, Innate Pharma reported cash, cash equivalents, and financial assets totaling €25.4 million, indicating robust liquidity management that supports future R&D and operational needs.
- Financial Liabilities: At the same date, the company's financial liabilities stood at €20.3 million, reflecting a manageable debt level that suggests prudent use of financial leverage, thereby reducing financial risk.
- Significant Revenue Growth: The company achieved revenue of €2.6 million in Q1, representing a 116.7% year-over-year increase, which highlights Innate Pharma's success in market demand and product promotion, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With rapid revenue growth and a solid financial position, Innate Pharma's competitive edge in the biopharmaceutical sector is likely to strengthen, attracting more investor interest in its future growth potential.
See More
Innate Pharma Reports Clinical Progress and Financial Update
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in cutaneous T-cell lymphoma in H2 2026, currently negotiating non-dilutive financing options to support this trial, indicating the company's ongoing commitment in this therapeutic area.
- Drug Safety and Efficacy: IPH4502 (Nectin-4 ADC) has shown a favorable safety profile and preliminary anti-tumor activity in its Phase 1 trial, with the maximum tolerated dose reached and enrollment nearing completion, suggesting significant potential in treating advanced solid tumors.
- Collaborative Research Advancements: The PACIFIC-9 Phase 3 trial, in collaboration with AstraZeneca, is progressing towards a planned data readout in H2 2026, reflecting positive developments in the company's strategic partnerships in non-small cell lung cancer.
- Financial Position: As of March 31, 2026, Innate Pharma reported cash and cash equivalents of €25.4 million, with an anticipated cash runway extending into Q3 2026, demonstrating robust financial management amid ongoing clinical developments.
See More
